| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.9 |
| mRNA | BIRB 0796 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |